Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | POLD1 | P28340 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596610 | 1.00 | BCHE (0.42) | BCHETK1CYP3A4CYP2C9TYMS | |
| SCHEMBL14627712 | 0.96 | TYMS (0.41) | BCHETK1CYP3A4CYP2C9TYMS | |
| SCHEMBL14627739 | 0.96 | TYMS (0.41) | BCHETK1CYP3A4CYP2C9TYMS | |
| SCHEMBL14627740 | 0.92 | TERT (0.42) | BCHETK1CYP3A4CYP2C9TYMS | |
| SCHEMBL23721012 | 0.88 | CYP3A4 (0.55) | BCHETK1CYP3A4CYP2C9TYMS | |
| SCHEMBL13660305 | 0.85 | CYP3A4 (0.46) | BCHETK1CYP3A4CYP2C9TYMS | |
| SCHEMBL14596598 | 0.85 | ALDH1A1 (0.48) | BCHECYP3A4CYP2C9POLB | |
| SCHEMBL21316792 | 0.85 | ALDH1A1 (0.48) | BCHECYP3A4CYP2C9POLB | |
| SCHEMBL14596608 | 0.84 | POLB (0.61) | BCHETK1TYMSPOLBPOLA1 | |
| SCHEMBL14596612 | 0.84 | POLB (0.61) | BCHETK1TYMSPOLBPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | BCHE 4117/4885TK1 45/4885CYP3A4 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.